Mar 13, 2023 / 07:30PM GMT
Jonathan Ashcoff - ROTH MKM - Analyst
Again, I'm Jonathan Ashcoff, Senior Biotechnology Analyst at ROTH MKM. And now with us we have Rob Etherington, the CEO of Clene Inc.
Rob Etherington - Clene Inc. - President & CEO
Thank you, Jonathan. Pleasure to be here.
Jonathan Ashcoff - ROTH MKM - Analyst
Welcome, Rob.
Questions and Answers:
Jonathan Ashcoff - ROTH MKM - AnalystSo let's discuss your main product, CNM-Au8. A lot of people are probably unfamiliar with it. How does it work? What makes it unique? Is this alchemy or is this really gold?
Rob Etherington - Clene Inc. - President & CEO
So it's a -- CNM-Au8 is a gold nanocrystal suspension. The only such drug of its type that we are aware where the therapy is the asset itself. In other words, there's gold nanocrystals that one could use for drug delivery, there's gold nanocrystals that one could use to paint an asset, another asset on, there's gold nanocrystals